Ad Code: 55240
ASH 2022: Leukemia eBook
Focus on ASH Leukemia 2023.indd
Read More
Factors Associated With Improved COVID-19 Outcomes for CLL
Patients with chronic lymphocytic leukemia (CLL) infected with COVID-19 during the most recent...
Read More
MRD by qPCR Prognostic of Outcomes in Venetoclax-Treated, NPM1-Mutated AML
Measurable/minimal residual disease (MRD) assessment by qPCR was strongly associated with clinical...
Read More
Excellent Results for Triplet Regimen in FLT3-Mutated AML
The triplet combination of azacitidine, venetoclax, and gilteritinib induced high response rates...
Read More
Ibrutinib Delays Need for Next Treatment in Real-World First-Line CLL
A new, real-world study using more than 2 years of EMRs shows that patients with chronic...
Read More
Blinatumomab Candidate for Standard-of-Care in Newly Diagnosed B-ALL
measurable residual disease (MRD)-negative showed an overall survival (OS) benefit if they were...
Read More
Novel Therapy May Replace Standard-of-Care Prophylaxis for GVHD
Post-transplant cyclophosphamide/tacrolimus/mycophenolate mofetil outperformed...
Read More
Intensive Chemotherapy Prior to Allo-HCT in Rel/Ref AML?
Intensive chemotherapy, in advance of allogeneic hematopoietic cell transplantation (allo-HCT),...
Read More
Ibrutinib Plus Venetoclax Displays Long-Term Benefits in CLL
The 5-year follow-up data of the CAPTIVATE study demonstrated that first-line ibrutinib plus...
Read More
High-Dose Methotrexate or Standard Interim Maintenance in Young Patients with ALL?
High-dose methotrexate was not associated with a reduction in the risk for CNS relapse compared...
Read More
Promising Results for Triplet Therapy With Magrolimab in AML
Triplet therapy of azacitidine, venetoclax, and magrolimab was safe as first-line therapy in...
Read MoreFriday Satellite Symposia
FSS are industry-supported, CME-certified symposia. These sessions are not part of the official ASH annual meeting program and are planned solely by the sponsoring company. Morning Topics: A Thread To Pull: Unraveling The...
Read MoreASH Foundation Run & Walk
The ASH Foundation Run & Walk will start and finish on Convention Center Boulevard and Julia Street, head toward the Riverwalk near the Audubon Aquarium of the Americas, and go through Woldenberg Park. Schedule: 7:00 a.m....
Read MoreHealth and Safety Protocols
Key Protocols: Vaccination will be required for all in-person meeting attendees. ASH is offering complimentary* medical evacuation and quarantine support coverage. Proof of a negative COVID-19 test is not required for in-person...
Read MoreASH Schedule At A Glance
Friday, December 9th 7:00 a.m.– 6:00 p.m. Registration open (for in-person participants) 7:00 a.m. – 10:00 a.m. Friday Satellite Symposia 9:00 a.m. – 12:00 Training Program Directors’ Workshop 11:00 a.m. – 2:00 p.m. Friday...
Read More
Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Secondary Hematological Malignancies
Patients with aggressive hematological malignancies and second primary malignancies can develop in...
Read More
Initial Treatment for CLL/ SLL: Ibrutinib Plus Fludarabine, Cyclophosphamide, and Rituximab
For a study, researchers sought to determine if ibrutinib combined with fludarabine,...
Read More
Ibrutinib Treatment for CLL/SLL: Overall and Subgroup Results from the Third Interim Analysis of FIRE
FIRE is a noninterventional, multicenter observational trial of patients in France receiving...
Read More
CLL/SLL Patients: Real-World Outcomes with First-Line Ibrutinib (Ibr) VS. Chemoimmunotherapy (CIT)
With the development of cutting-edge drugs like Ibr, the treatment landscape for CLL/SLL has...
Read More